Frank Bhatt

Frank Bhatt has contributed to clinical research establishing IO plus chemotherapy combinations as standard first-line therapy for advanced NSCLC regardless of PD-L1 expression. His research has examined the KEYNOTE-189 and KEYNOTE-407 trials establishing pembrolizumab plus platinum doublet as first-line standard for nonsquamous and squamous advanced NSCLC respectively, and how these regimens compare to pembrolizumab monotherapy in PD-L1-high patients. He has investigated predictive biomarker strategies to identify patients with PD-L1 >=50% NSCLC who are optimally treated with pembrolizumab alone versus IO plus chemotherapy combination, seeking to avoid over-treatment while optimizing outcomes. His translational work on genomic and immune determinants of differential benefit from IO versus IO plus chemotherapy in NSCLC has contributed to precision first-line treatment selection strategies.